FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a combination for preventing or treating a malignant tumour containing (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or its pharmaceutically acceptable salts and an immune control point inhibitor.
EFFECT: composition of the present invention achieves the excellent effect of treating a malignant tumour.
10 cl, 3 ex, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER, INCLUDING A VESSEL-DESTROYING AGENT AND A TAXANE COMPOUND | 2019 |
|
RU2761826C1 |
| COMBINED COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING BENZOPHENONE-THIAZOLE DERIVATIVES AS VDA AND TOPOISOMERASE INHIBITOR | 2017 |
|
RU2724341C1 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| COMBINATION CONTAINING MULTIFUNCTIONAL ANTIBODIES REDIRECTING T-CELLS AND CONTROL POINT MODULATORS, AND ITS APPLICATIONS | 2017 |
|
RU2773655C2 |
